Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GoodRx vs Meto

GoodRx
Graded #116

Higher grade

vs+7.599999999999994
Meto
Graded #278

Lower grade

The verdict

GoodRx takes it — 69.6/100 to 62/100.

GoodRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GoodRx (NASDAQ: GDRX) is the largest US prescription savings platform.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGoodRx +35
80
45
Dose & formulationGoodRx +30
70
40
Clinical oversightMeto +19
69
88
Labs & monitoringMeto +34
51
85
FulfillmentGoodRx +14
81
67
Contract termsEven
55
55
GoodRx · left barMeto · right bar

The numbers

MetricGoodRxMeto
WeighScore69.6/10062/100
GradeCC
Scorecard rank#116#278
SemaglutideNot disclosedNot disclosed
Tirzepatide$299/mo (brand Zepbound)Not disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
GoodRx

Graded #116 · C

Strengths

  • $149/month self-pay for brand-name Foundayo (orforglipron) — matches the lowest cash price at launch, far below typical retail
  • $299/month self-pay for Zepbound KwikPen — well under Lilly's typical cash list price
  • Honored at 70,000+ US pharmacies — the largest retail redemption network of any GLP-1 channel we cover
  • No membership fee — bring your own prescription and present the discount card at the pharmacy counter
  • Brand-name FDA-approved medication, not compounded

Where it loses points

  • Requires a valid prescription — GoodRx is a discount card, not a prescriber; you still need a clinician to write the script
  • Self-pay only — does not apply toward insurance benefits or deductibles
  • Headline price applies to the lowest Foundayo dose; higher doses may cost more
  • No compounded GLP-1 options — not the channel for compounded semaglutide or tirzepatide
  • Pricing can change as Lilly's manufacturer coupon program evolves
Meto

Graded #278 · C

Strengths

  • Accepts major insurance (Blue Cross, Anthem, United, Aetna) — most patients pay $0–50 per visit
  • Requires lab work before prescribing GLP-1s; addresses root-cause metabolic drivers
  • Matches patients with endocrinologists and obesity medicine specialists within minutes
  • Offers compounded semaglutide and tirzepatide with board-certified physician oversight
  • Handles all prior-auth paperwork; provider location pages exist for all 50 US states

Where it loses points

  • Medication pricing fully gated behind quiz — no public cash price for sema or tirz
  • Lab panels are a separate out-of-pocket cost ($199–$399) unless covered by insurance
  • No LegitScript certification or named compounding pharmacy found on any public page
  • Company leadership and clinical team not disclosed publicly
  • Self-pay cash pricing exists per site copy but is not published anywhere

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard